Compumedics (ASX:CMP) Moat Score: 0/10 (As of Jun. 24, 2026)


ASX:CMP Compumedics Ltd ASX:CMP
61 GF Score
Price A$0.26
GF Value A$0.31
Valuation Modestly Undervalued
! 4 Warning Signs
View Full Analysis

What is Compumedics Moat Score?

Compumedics has the Moat Score of 0, which implies that the company might have No Moat - No discernible moat.

Compumedics has

Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more.

The company's Moat Score is based on these criteria:

1. Market leadership and sustainable market share
2. Network effects and significant customer switching costs
3. Valuable intellectual property and patents
4. Strong brand strength and deep customer loyalty
5. Durable cost advantages (e.g., economies of scale, proprietary technology)
6. Significant regulatory barriers and exclusive licenses
7. Superior distribution network
8. Strong and sustainable pricing power
9. Consistent and impactful innovation and R&D capabilities

Based on the research, GuruFocus believes Compumedics might have No Moat - No discernible moat.

Compumedics  (ASX:CMP) Moat Score Explanation

The Moat Score ranges from 0 to 10, with 10 as the highest. GuruFocus divided Moat Score into following 8 categories:

Moat Score Moat Level
10Wide Moat - Exceptionally dominant and durable wide moat
8 - 9Wide Moat - Clear and robust wide moat
7Wide Moat - Entry-level wide moat, clearly possessing durable advantages
6Narrow Moat - Strong narrow moat, clearly distinguishable but not wide
5Narrow Moat - Solid narrow moat
4Narrow Moat - Discernible but modest moat
1 - 3No Moat - Very weak/transient advantages
0No Moat - No discernible moat

Compumedics Moat Score Related Terms

ASX:CMP
61GF Score
Compumedics Ltd ASX:CMP
Moat Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Compumedics (ASX:CMP) Overvalued in 2026?

Based on GuruFocus' analysis, Compumedics stock appears to be undervalued. The current stock price of A$0.26 is trading 17.7% below its estimated GF Value™ of A$0.31. GuruFocus considers Compumedics to be Modestly Undervalued.

Key valuation signals for ASX:CMP:

  • Moat Score: 0
  • GF Value™: A$0.31 vs. price of A$0.26 (17.7% below fair value)
  • GF Score™: 61/100 with 4 warning signs

No single metric tells the full story. See the ASX:CMP stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Compumedics Business Description

Address 30-40 Flockhart Street, Abbotsford, Melbourne, VIC, AUS, 3067
Compumedics Ltd is a medical device company. It is engaged in the development, manufacturing, and commercialization of diagnostic technologies for sleep, brain, and ultrasonic blood-flow monitoring applications. The company is organized into geographical operating segments, being the United States of America, Australia and Asia Pacific, and Europe and the Middle East. It derives a majority of its revenue from Australia and the Asia Pacific region.
61GF Score

Get the complete analysis for ASX:CMP

Moat Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

A$0.26
Price
A$0.31
GF Value